Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma

The purpose of this study is to test a new medication called Mosunetuzumab to see if it can help people with Extranodal Marginal Zone Lymphoma (EMZL). This study will include people who have not yet received any treatment for cancer and whose cancer is in stage I-IV. This study will help doctors understand if Mosunetuzumab improves outcomes in people with EMZL and if it is safe to use.

Trial Details

NCT ID

NCT06569680

Phase

PHASE2

Sponsor

Izidore Lossos, MD

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

Mosunetuzumab

Locations (sample)

Miami, Florida, United States|25.77427,-80.19366

Key Eligibility Criteria

Men and women aged 18 years or older at the time of signing informed consent.
Able and willing to sign the informed consent form (ICF).
Ability to comply with the trial protocol.
Histologically confirmed EMZL presenting with stage I-IV disease.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →